比美珠单抗市场：依适应症、年龄层、性别、最终用户、通路和地区划分

预计到 2025 年，bimekizumab 市场规模将达到 15.2 亿美元，预计到 2032 年将达到 56.1 亿美元，2025 年至 2032 年的复合年增长率为 20.5%。

全球比美珠单抗市场是生物製药行业中一个快速发展的细分市场，其核心是新型单株抗体疗法，该疗法能够选择性地抑制白细胞介素-17A和白细胞介素-17F两种细胞激素。作为一种创新免疫调节剂，比美珠单抗已成为治疗多种自体免疫发炎疾病（尤其是干癣、干癣性关节炎、僵直性脊椎炎及其他相关发炎性疾病）的极具前景的治疗选择。这种双重抑制IL-17A/F的机制使比美珠单抗区别于现有的IL-17抑制剂，有望提高治疗效果并改善患者预后。

市场成长的主要驱动力是全球自体免疫疾病盛行率的不断上升、人们对先进生物疗法的认知度不断提高以及对标靶免疫疗法解决方案需求的不断增长。主要医药市场监管机构的核准已使bimekizumab成为生物治疗市场的重要竞争者。製药业对精准医疗和个人化治疗方案的持续关注也进一步加速了市场接受度。与传统的单标靶治疗相比，医疗服务提供者越来越认识到双重细胞激素抑制的潜在优势，这有助于扩大临床应用范围，并提高市场渗透率，惠及寻求有效长期控制慢性发炎性疾病的各类患者群体。

市场动态

全球比美珠单抗市场正经历强劲增长，其主要驱动因素包括银屑病、干癣性关节炎和僵直性脊椎炎自体免疫疾病在全球范围内的日益普及。这些疾病共影响数百万患者，因此亟需有效的治疗方法。临床试验中展现出的卓越疗效，尤其是其双重IL-17A/F抑制机制（与单靶点竞争药物相比，该机制显着提升了治疗效果），是推动市场成长的关键因素。此外，医疗保健支出不断增长以及生物製药疗法的日益普及也促进了市场发展。医疗专业人员对先进免疫调节疗法的认知不断提高，诊断能力的不断提升，以及已开发市场有利的报销政策，都为患者提供了便利。

然而，市场成长仍面临诸多限制因素。生物製药的高昂成本限制了其可近性，尤其是在医疗预算有限的新兴经济体。此外，严格的监管核准流程需要大量的临床证据，潜在的安全隐患（例如免疫抑制导致的感染风险增加）以及来自现有IL-17抑制剂和其他替代生物疗法的激烈竞争也是挑战。单株抗体的生产复杂性和供应链挑战也构成营运方面的阻碍因素。

然而，随着适应症扩展到目前正在进行临床试验的其他自体免疫疾病，随着医疗基础设施的改善，新兴经济体的市场渗透率不断提高，联合治疗的开发可能改善治疗效果，更加註重个性化医疗方法，以及专利到期后生物类似药的潜在开发，这些都带来了巨大的机会，从而使更广泛的患者群体能够获得市场准入和负担得起。

本次调查的主要特点

• 本报告对全球比美珠单抗市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）内的市场规模（十亿美元）和復合年增长率（%）。
• 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 该研究根据以下参数对全球 Bimekizumab 市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 本研究涵盖的主要企业包括 UCB。
• 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
• 这份全球比美珠单抗市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员可以透过全球 Bimekizumab 市场分析中使用的各种策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要

第三章 市场动态、监管与趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 法规环境
• 产品上市及核准
• PEST分析
• 波特分析
• 併购趋势
• 产业趋势

4. 2020-2032年全球比美珠单抗市场（依适应症划分）

• 斑块型干癣
• 干癣性关节炎
• 中轴型脊椎关节炎
• 非放射性中轴型脊椎关节炎（nraxSpA）
• 其他研究性自体免疫疾病适应症

5. 2020-2032年全球比美珠单抗市场依年龄组别划分

• 成人
• 老年人

6. 2020-2032年全球比美珠单抗市场依性别划分

• 男性
• 女士

7. 2020-2032年全球比美珠单抗市场（依最终用户划分）

• 医院
• 皮肤科诊所
• 风湿病诊所
• 专业医疗中心

8. 2020-2032年全球比美珠单抗市场依通路划分

• 医院药房
• 零售药房
• 网路药房

9. 2020-2032年全球比美珠单抗市场（依地区划分）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第十章 竞争格局

• UCB

第十一章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十二章 参考文献与调查方法

• 参考
• 调查方法
• 关于本公司

Bimekizumab Market is estimated to be valued at USD 1.52 Bn in 2025 and is expected to reach USD 5.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 20.5% from 2025 to 2032.

Global bimekizumab market represents a rapidly evolving segment within biopharmaceutical industry, centered around a novel monoclonal antibody therapeutic that selectively inhibits both interleukin-17A and interleukin-17F cytokines. Bimekizumab, developed as an innovative immunomodulatory agent, has emerged as a promising treatment option for various autoimmune inflammatory conditions, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and other related inflammatory disorders. This dual IL-17A/F inhibition mechanism distinguishes bimekizumab from existing IL-17 inhibitors, potentially offering enhanced therapeutic efficacy and improved patient outcomes.

The market's growth trajectory is primarily driven by increasing prevalence of autoimmune diseases globally, rising awareness about advanced biologic therapies, and growing demand for targeted immunotherapy solutions. Regulatory approvals across major pharmaceutical markets have positioned bimekizumab as a significant competitor in the biologic therapeutics landscape. The pharmaceutical industry's continued focus on precision medicine and personalized treatment approaches has further accelerated market adoption. Healthcare providers increasingly recognize the potential benefits of dual cytokine inhibition compared to traditional single-target therapies, contributing to expanding clinical applications and market penetration across diverse patient populations seeking effective long-term management of chronic inflammatory conditions.

Market Dynamics

The global bimekizumab market experiences robust growth driven by several key factors, including the escalating worldwide prevalence of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, which collectively affect millions of patients seeking effective treatment alternatives. The superior efficacy profile demonstrated in clinical trials, particularly the dual IL-17A/F inhibition mechanism that provides enhanced therapeutic outcomes compared to single-target competitors, serves as a primary market driver alongside increasing healthcare expenditure and growing adoption of biologic therapies. Rising awareness among healthcare professionals about advanced immunomodulatory treatments and expanding diagnostic capabilities contribute to market expansion, while favorable reimbursement policies in developed markets facilitate patient access.

However, market growth faces significant restraints including the exceptionally high cost of biologic therapies that limits accessibility, particularly in emerging economies with constrained healthcare budgets, stringent regulatory approval processes requiring extensive clinical evidence, potential safety concerns associated with immunosuppression including increased infection risks, and intense competition from established IL-17 inhibitors and other biologic alternatives. Manufacturing complexities and supply chain challenges for monoclonal antibodies also pose operational constraints.

Nevertheless, substantial opportunities emerge through expanding applications to additional autoimmune indications currently under clinical investigation, growing market penetration in emerging economies with improving healthcare infrastructure, development of combination therapies that could enhance treatment outcomes, increasing focus on personalized medicine approaches, and potential biosimilar development following patent expiration that could improve market accessibility and affordability for broader patient populations.

Key Features of the Study

• This report provides in-depth analysis of the global bimekizumab market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bimekizumab market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study include UCB
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bimekizumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bimekizumab market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Non-radiographic axial spondyloarthritis (nraxSpA)
  • Other Investigational Autoimmune Indications
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Dermatology Clinics
  • Rheumatology Clinics
  • Specialty Care Centers
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • UCB

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Bimekizumab Market, By Indication
  • Global Bimekizumab Market, By Age Group
  • Global Bimekizumab Market, By Gender
  • Global Bimekizumab Market, By End User
  • Global Bimekizumab Market, By Distribution Channel
  • Global Bimekizumab Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Bimekizumab Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Plaque Psoriasis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Psoriatic Arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Axial Spondyloarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-radiographic axial spondyloarthritis (nraxSpA)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Investigational Autoimmune Indications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Bimekizumab Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bimekizumab Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bimekizumab Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Dermatology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rheumatology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Care Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Bimekizumab Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Bimekizumab Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• UCB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us